title: Evaluation of safety and efficacy of supirocin-B (mupirocin 2% + betamethasone dipropionate 0.05%) in infected dermatoses--a post marketing study.
abstract: The aim of the present post marketing study was to study the safety and efficacy of supirocin-B ointment (mupirocin 2% + betamethasone dipropionate 0.05%) in the treatment of infected dermatoses. For this purpose physicians from different parts of India were requested to keep the clinical records prospectively as per a specially designed proforma over a follow-up period of 7 days, whenever they prescribed supirocin-B ointment (mupirocin 2% + betamethasone dipropionate 0.05%) for local application, three times a day, to their patients having either primary infection complicated by dermatoses or dermatoses infected secondarily. From the analysis of 251 clinical records contributed by 27 physicians, it was evident that in clinical practice, supirocin-B ointment (mupirocin 2% + betamethasone dipropionate 0.05%) was found to be safe and very effective by physicians in the treatment of infected dermatoses in 94.8% of the patients. Similarly 92.4% of the patients reported more than 70% improvement in their symptoms after 7 days of treatment. No adverse effects were reported during the treatment period by any of the patients except worsening of skin lesions by one patient. Thus from this study, supirocin-B ointment (mupirocin 2% + betamethasone dipropionate 0.05%) seems to be safe and effective in the treatment of infected dermatoses.
authors.affiliation: Department of Skin & STD, Nanavati Hospital & Medical Research Centre, Mumbai.
authors.forename: S
authors.initials: S
authors.lastname: Savant
authors.forename: V R
authors.initials: VR
authors.lastname: Janaki
authors.forename: R R
authors.initials: RR
authors.lastname: Mittal
authors.forename: S
authors.initials: S
authors.lastname: Sengupta
authors.forename: A
authors.initials: A
authors.lastname: Desai
mesh_terms: D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004338:Drug Combinations; D006801:Humans; D007194:India; D016712:Mupirocin / Q000008:administration & dosage* / Q000009:adverse effects; D009824:Ointments; D011358:Product Surveillance, Postmarketing; D011711:Pyoderma / Q000188:drug therapy*; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D009824:Ointments; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D016712:Mupirocin